key: cord-0701328-zkc4s4q3
authors: Jacobson, Karen B; Pinsky, Benjamin A; Montez Rath, Maria E; Wang, Hannah; Miller, Jacob A; Skhiri, Mehdi; Shepard, John; Mathew, Roshni; Lee, Grace; Bohman, Bryan; Parsonnet, Julie; Holubar, Marisa
title: Post-vaccination SARS-CoV-2 infections and incidence of presumptive B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center
date: 2021-06-17
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab554
sha: 314d0ea18b7902650244b64dd68e19ea6a45052f
doc_id: 701328
cord_uid: zkc4s4q3

BACKGROUND: Although mRNA-based SARS-CoV-2 vaccines report ≥90% efficacy, breakthrough infections occur. Little is known about the effectiveness of these vaccines against SARS-CoV-2 variants, including the highly-prevalent B.1.427/B.1.429 variant in California.. METHODS: In this quality improvement project, we collected demographic and clinical information from post-vaccine SARS-CoV-2 cases (PVSCs), defined as health care personnel (HCP) with positive SARS-CoV-2 NAAT after receiving ≥1 vaccine dose. Available specimens were tested for L452R, N501Y and E484K mutations by RT-PCR. Mutation prevalence was compared among unvaccinated, early post-vaccinated (<=14 days after dose 1), partially vaccinated (positive test >14 days after dose 1 and ≤14 days after dose 2) and fully vaccinated (>14 days after dose 2) PVSCs. RESULTS: From December 2020-April 2021, >=23,090 HCPS received at least1 dose of an mRNA-based SARS-CoV-2 vaccine, and 660 HCP cases of SARS-CoV-2 occurred of which 189 were PVSCs. Among the PVSCs, 114 (60.3%), 49 (25.9%) and 26 (13.8%) were early post-vaccination, partially vaccinated, and fully vaccinated, respectively. Of 261 available samples from vaccinated and unvaccinated HCP, 103 (39.5%), including 42 PVSCs (36.5%), had L452R mutation presumed to be B.1.427/B.1.429,. When adjusted for community prevalence of B.1.427/B.1.429, PVSCs did not have significantly elevated risk for infection with B.1.427/B.1.429 compared with unvaccinated HCP. CONCLUSIONS: Most PVSCs occurred prior to expected onset of full, vaccine-derived immunity. Presumptive B.1.427/B.1.429 was not more prevalent in post-vaccine cases than in unvaccinated SARS-CoV-2 HCP. Continued infection control measures, particularly ≤14 days post-vaccination, and continued variant surveillance in PVSCs is imperative to control future SARS-CoV-2 surges.

, was first detected in the spring of 2020 and by January 2021 accounted for 35-50% of all SARS-CoV-2 cases detected in California. (9, 12) Studies indicate reduced neutralizing activity of naturally-, vaccine-acquired and monoclonal antibodies against these variants including B.1.427/B.1.429 (13) (14) (15) (16) (17) (18) , and possibly increased transmissibility (11, 19) and virulence. Humoral immunity, however, is not the only factor in determining protection against infection (20) and more real-world data is needed to determine effectiveness of the available SARS-CoV-2 vaccines against SARS-CoV-2 and its variants. 

On December 18, 2020, SHC began vaccinating HCP with Pfizer mRNA SARS-CoV-2 vaccine, initially to patient-facing frontline HCP in high acuity settings, expanding to all patient-facing frontline HCP on December 28, and finally to all health system employees beginning January 8, 2021. Moderna mRNA vaccine was available as of January 22, 2021. All HCP were required to self-monitor for COVID-related symptoms and attest to the absence of those symptoms every day when they entered the medical campus using a mandatory digital application. If any symptoms were reported, HCP underwent testing through Occupational Health. Asymptomatic HCP with high risk occupational or community exposures (e.g. household contacts, part of contact tracing effort after a work-related exposure) also were tested by Occupational Health. In addition, all HCP working on campus were strongly encouraged to participate in voluntary weekly asymptomatic testing using selfcollected swabs that were processed using the Color platform. (21) HCPs tested at non-SHC facilities were required to report any positive tests to Occupational Health.

A c c e p t e d M a n u s c r i p t 7

Post-vaccine SARS-CoV-2 cases (PVSCs) were defined as individuals identified by occupational health case notification and chart extraction with a positive SARS-CoV-2 nucleic acid amplification testing (NAAT) after receiving at least one dose of a SARS-CoV-2 vaccine. Initial respiratory SARS-CoV-2 NAAT was conducted on a variety of platforms (22) (23) (24) including: 1) a previously-described laboratory-developed reverse transcription 

Of approximately 30,000 eligibile HCPs, at least 23,090 received >=1 dose of the Pfizer Of the seven immunocompromised PVSCs, three were positive for SARS-CoV-2 early postvaccination, two were partially vaccinated, and two were fully vaccinated; six were symptomatic and none required hospitalization. In unadjusted analysis, PVSCs infected with L452R-containing viruses were more likely than those with no identified mutations to have tested positive after the second vaccine dose, or to be partially-or fully-vaccinated at time of positive test ( A c c e p t e d M a n u s c r i p t 13

In this cohort of HCP at an academic medical center in Northern California, similar to other reports elsewhere (5, 6), we found that SARS-CoV2 infection post-vaccination is uncommon despite widespread community disease. We identified only 189 such cases out of a total of >23,000 vaccinated HCP.(30) Not surprisingly, most of these cases occurred in the first 2 weeks after vaccination, before immunity is expected to develop. Whether these individuals were exposed before or after their vaccine dose cannot be known, although the dates of symptom onset combined with the typical incubation period of 5-9 days(31) suggests that some early cases were acquired prior to the first vaccine dose. In contrast, 26 PVSCs occurred >14 days after the second dose, when full immunity is expected. Although >85% of The peak in post-vaccine positive SARS-CoV-2 cases in late December 2020 to early January 2021 corresponds with a rise in county-wide cases and HCP cases at that time. We did not find any evidence to support transmission clusters or superspreading events contributing to post-vaccination SARS-CoV-2 infections within the health care system.

Although several PVSCs had been vaccinated on the same two days in December, nearly half of these infections occurred more than two weeks after vaccination, suggesting that exposure occurred sometime after the date of vaccination. Further, 41.8% reported household contacts with known SARS-CoV-2 infection at the time of their positive test, suggesting community transmission was driving these cases rather than workplace exposure; the multiple cases in late December and early January may have been related to holiday celebrations. This highlights the importance of maintaining social distancing and diligent mask wearing at work in the setting of increased prevalence of variants. Describing A c c e p t e d M a n u s c r i p t 15 the phenomenon of PVSCs in this quality improvement project has allowed us to more effectively promote these measures within our system at a time when many are tempted to loosen precautions due to "pandemic fatigue" and a sense of security after being vaccinated.

We do note several limitations in this report. We did not obtain detailed demographic and 

This project was not formally funded. Karen Jacobson is supported by T32 Training Grant Number 5T32AI052073-14.

None of the authors has potential conflicts to disclose. A c c e p t e d M a n u s c r i p t 21 *Mutation analysis was performed on n=261 HCPs. Mutation analysis was not available for 149 (22 .6%) who were tested outside the SHC laboratory, 43 (6.5%) did not meet C t or RLU value criteria, 114 (17.3%) with insufficient quantity, 6 (0.9%) that failed amplification, and 87 (13.2%) that were discarded or otherwise unavailable. A c c e p t e d M a n u s c r i p t 25 A c c e p t e d M a n u s c r i p t 26 A c c e p t e d M a n u s c r i p t 27 *This specimen had a blunted E484K amplification curve which was revealed to represent an E484Q mutation by sequencing. (29) A c c e p t e d M a n u s c r i p t M a n u s c r i p t 29 Figure 1 

COVID-19 Dashboard by the Center for Systems Science and Engineering

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight

Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening

Emergence of a Novel SARS-CoV-2 Variant in Southern California

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv

Global initiative on sharing all influenza data -from vision to reality

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. bioRxiv

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. bioRxiv

SARS-CoV-2 immune

Estimation of secondary household attack rates for emergent SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco. medRxiv

Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees

CA: Color

Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2

Genotyping PCR for Population-Level Variant Screening and Epidemiologic Surveillance. medRxiv. 2021:2021.04.20.21255480. 26. Pangolin: lineage assignment in an emerging pandemic as an epidemiological tool

Genotyping PCR for Population-Level Variant Screening and Epidemiologic Surveillance

A modified poisson regression approach to prospective studies with binary data

Identification of a SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations

Serial interval and incubation period of COVID-19: a systematic review and meta-analysis

Post-Vaccination COVID-19 among Healthcare Workers

Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2